What Is Retinalamin? The Registered Retina Peptide Medicine, Examined
Retinalamin is a registered Russian retina-extract medicine (Geropharm, ATC S01XA), unapproved in the EU/US. A sober look at what its literature actually shows.
Retinalamin is a prescription medicine registered in Russia and some CIS states: a lyophilised complex of water-soluble bovine-retina polypeptides under 10 kDa, injected for glaucoma and retinopathy. It is not approved by the EMA or FDA, and its evidence base is limited and single-school.
Retinalamin (Ретиналамин) sits in an unusual category: a genuine, registered prescription medicine in one part of the world that is completely unknown to regulators in another. In Russia it is an ophthalmology drug you inject; in the European Union and the United States it does not exist as an approved product at all. That gap — real registration on one side, regulatory silence on the other — is the whole story, and it is worth reading carefully rather than through marketing. Everything below describes registered-drug information and published laboratory and clinical literature, not use in people.
What is Retinalamin, exactly?
Retinalamin is a registered Russian medicine manufactured by Geropharm, sold as a lyophilisate for intramuscular or parabulbar injection at 5 mg per vial, typically ten vials to a pack.1 Its registration number is ЛС-000684, later renewed as ЛП-№(000519)-(РГ-RU) with an entry dated 21 January 2022, and it carries the anatomical-therapeutic-chemical code S01XA — the „other ophthalmologicals“ class.1,2 On paper it is a prescription-only drug with a defined dosage form and an approved indication list, corroborated by independent Russian drug registries.2
What it is not is a single, named molecule. The drug substance is described as a complex of water-soluble polypeptide fractions with molecular weight below 10 kDa, extracted from cattle (bovine) retina, with 17 mg of glycine as a stabiliser. There is no international nonproprietary name — the grouping term is literally „cattle retinal polypeptides.“1 This matters for anyone trying to reason about it chemically. Retinalamin belongs to the same organ-extract „peptide bioregulator“ tradition as Cortexin (brain), Thymalin (thymus), Epithalamin (pineal) and Prostatilen (prostate)13 — heterogeneous tissue extracts, not the short, defined, synthetic sequences of the Cytogen and Khavinson peptide line such as Epitalon or Vesugen. There is no meaningful single CAS number for a mixture like this. If you want the fuller picture of that whole family, the Khavinson bioregulators overview and the Cortexin explainer are the natural companions, and the organ-by-organ guide maps where each one is claimed to act.
What is it registered for, and where?
The Russian label lists a specific set of ophthalmology indications: compensated primary open-angle glaucoma, diabetic retinopathy, post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy, myopia as an adjunct, and post-operative rehabilitation after surgery for rhegmatogenous or traumatic retinal detachment.1,2 Its registered use is clinical, by parabulbar or intramuscular injection in short courses, and that is noted here strictly as registered-drug information, not as guidance for any use, because this is a foreign prescription medicine and not a material Condor supplies.
The geographic boundary is sharp. Retinalamin has no marketing authorisation in the EU, the UK or the US; its clinical footprint is Russia and several CIS and post-Soviet markets.1 Neither the European Medicines Agency nor the FDA has evaluated and approved it. That absence is not a bureaucratic accident of geography — it means no regulator outside the Russian/CIS sphere has judged the efficacy and safety dossier sufficient for marketing.
<10 kDa The entire drug is defined by a molecular-weight cutoff, not a sequence — an undefined polypeptide fraction, not a characterised molecule.
What is the proposed mechanism?
The manufacturer frames Retinalamin as a retina-tropic „retinoprotector“ acting on photoreceptors and glial (Müller) cells, said to normalise vascular permeability and counter oxidative stress and glutamate excitotoxicity.1 The strongest experimental support for that framing is a radioligand-binding and biodistribution study reporting that the polypeptide preparation binds AMPA, NMDA and mGluR1 glutamate-receptor subtypes and reaches eye and brain tissue after intravenous, intramuscular and parabulbar dosing.3 That is a coherent anti-excitotoxic hypothesis — glutamate excitotoxicity is a plausible route to retinal ganglion-cell death — though the paper is manufacturer-affiliated.
In cell culture, the preparation was non-cytotoxic across 0.009–5 mg/mL, and adding it alongside an excitotoxic glutamate challenge raised the viable-cell fraction from 9% to 51.6% versus control in isolated mouse retinal cells.4 Foundational work from the Khavinson laboratory earlier reported that the retina polypeptide preparation „tissue-specifically“ stimulated proliferation of retinal and pigment-epithelial cells,11 and, in an amphibian gastrula-ectoderm assay, influenced neuronal and retinal differentiation in a concentration-dependent way.12 Read together, these give an in-vitro and developmental-biology signal consistent with the marketed mechanism — but they are all in-vitro or model-organism findings from a single lab.
A coherent mechanism on paper is not the same as demonstrated efficacy in the eye — and here the two diverge sharply.
What does the clinical literature actually show?
The human data are real but modest, open-label-heavy, and built on surrogate endpoints. The table below summarises the anchor studies as reported.
| Study (ref) | Design & size | Reported endpoint | What it shows |
|---|---|---|---|
| Glaucoma, 24-month6 | Randomized, 147 POAG patients (249 eyes) | RNFL / neuroretinal rim structure, visual-field PSD | Controls lost tissue; treated group less so — but most between-group differences non-significant, both groups‘ fields worsened |
| Route comparison7 | Open-label, 498 POAG eyes | Retinal light sensitivity (perimetry) | Peak at 3 months, regressing by 6; no placebo arm |
| Diabetic retinopathy8 | Controlled, 56 patients (112 eyes), unblinded | OCT ganglion-cell complex, PERG/ffERG | „Positive changes“ claimed, little quantitative detail |
| Retinal abiotrophy10 | Uncontrolled case series, 33 children | Visual acuity, ERG | Improvement in 82% (VA) / 37% (ERG); no control group |
All endpoints are structural or electrophysiological surrogates (OCT, ERG, perimetry), not long-term vision or blindness outcomes. Reported strictly as published literature, not as evidence of use or benefit; several studies are open-label or uncontrolled.
Older diabetic-macular-edema reports in elderly patients add to this small clinical corpus at low methodological rigor,9 and the diabetic-retinopathy line has recent controlled entries,8 but the overall picture is a handful of small, mostly Russian-language studies leaning on surrogate endpoints. For a comparison point among the injectable extracts, the Cerluten reference covers a related retina-directed bioregulator.
An honest read of the evidence
The most important fact about Retinalamin’s evidence is where it comes from. Virtually every supporting paper originates in one research tradition — the Khavinson / St Petersburg Institute of Bioregulation and Gerontology school — and appears in Russian-language journals, overwhelmingly Vestnik Oftalmologii, across roughly two dozen PubMed records spanning 2002–2025.3,11,13 There is essentially no independent replication in high-impact Western peer-reviewed ophthalmology. A single-school, single-country literature is a structural weakness regardless of how the individual studies read, and several of the key mechanistic and clinical papers are authored by, or affiliated with, the manufacturer or its research holding.3
More pointedly, the animal evidence is not even internally consistent. A controlled rabbit study of photochemical (405 nm) retinal damage — 36 rabbits, 72 eyes, with TUNEL histology and multifocal and full-field ERG — found no significant functional or morphological neuroprotection from parabulbar Retinalamin versus saline (p>0.05).5 That is a direct negative result in exactly the kind of model where a genuine retinoprotector should perform, and it undercuts any blanket „retinoprotector“ claim. It has to be stated plainly rather than buried.
The clinical trials compound the caution. They are small, largely open-label, and rest on surrogate endpoints — OCT layer thickness, ERG amplitudes, perimetric sensitivity — rather than hard, long-term visual outcomes. The evidence base includes uncontrolled case series in children10 and even single-modality reports. Even the largest randomized glaucoma study showed mostly non-significant between-group differences with visual-field indices worsening in both arms.6 And the chemistry sets a ceiling on confidence: an undefined bovine-tissue extract cannot be fully characterised, batch-to-batch consistency is hard to verify, and — like any animal-derived injectable — it carries theoretical bovine-source biological-safety considerations that were never assessed to EMA or FDA standards. The absence of Western approval, then, is best read as evidence of an unpersuasive dossier, not merely a quirk of geography. Retinalamin should be understood as a medicine registered in some jurisdictions on a limited, single-school evidence base — not as a proven retinoprotector.
All materials discussed by Condor Research are addressed on a Research Use Only (RUO), literature-and-reference basis. Retinalamin is a foreign registered medicine that Condor Research does not supply; there is no product, no certificate of analysis, and no purchase framing attached to it. Everything above is in-vitro, animal-model and published clinical literature only. It is not a dosing protocol, clinical guidance, a safety assessment, or medical advice for any organism, and it must not be read as such.
Condor Research · Wissenschaftlicher Support
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com
- It is a registered Russian Rx drug (Geropharm, No. ЛС-000684 / ЛП-№(000519)-(РГ-RU), ATC S01XA), sold as a 5 mg lyophilisate for intramuscular or parabulbar injection.
- The drug substance is not a defined molecule but a complex of bovine-retina polypeptide fractions under 10 kDa, stabilised with glycine — a tissue extract, like Cortexin, not a synthetic peptide.
- It has no marketing authorisation in the EU, UK or US; clinical use is confined to Russia and post-Soviet markets.
- The proposed mechanism is anti-excitotoxic retinoprotection; in vitro the mixture binds AMPA, NMDA and mGluR1 glutamate receptors.
- A controlled rabbit study found no significant neuroprotection versus saline, so even animal efficacy is inconsistent.
- Nearly all supporting papers come from one Russian research school (Khavinson / St Petersburg) in one journal, with no independent Western replication.
- Condor Research does not sell Retinalamin; this page is educational reference only.
Is Retinalamin a natural or synthetic peptide?
Neither in the usual sense. It is a mixture of water-soluble polypeptide fractions under 10 kDa extracted from cattle retina, stabilised with glycine. It has no INN and no single defining sequence, so it is best described as a bovine tissue extract rather than a synthetic peptide.
How is it different from the Cytogen or Khavinson synthetic peptides?
The synthetic Khavinson peptides such as Epitalon are short, defined amino-acid sequences. Retinalamin, like Cortexin and Thymalin, is an undefined organ extract in the "peptide bioregulator" class. The distinction matters for characterisation: a defined sequence can be verified molecule-by-molecule; a tissue extract can only be specified by fraction and molecular-weight cutoff.
What is the proposed mechanism of action?
The marketed rationale is anti-excitotoxic retinoprotection acting on photoreceptors and Müller glia. Supporting this, an in-vitro study reported binding to AMPA, NMDA and mGluR1 glutamate receptors, and cell-culture work showed protection against a glutamate excitotoxic challenge. These are mechanistic signals, not proof of clinical effect.
Does any study show it does not work?
Yes. A controlled rabbit model of photochemical retinal damage found no significant neuroprotection from Retinalamin compared with saline (p>0.05). That negative animal result is one reason the "retinoprotector" label should be treated cautiously rather than accepted at face value.
Why is it not sold in the EU or US?
It has never received a marketing authorisation from the EMA or FDA. No regulator outside the Russian/CIS sphere has judged its efficacy-and-safety dossier sufficient. Given a single-school evidence base and at least one negative controlled study, that regulatory absence is consistent with an unpersuasive body of evidence.
Does Condor Research offer Retinalamin?
No. This article is an educational reference on a registered foreign medicine, part of a broader look at the peptide bioregulator family. Condor Research does not supply Retinalamin, and nothing here is use, dosing or medical guidance.